# A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

> **NCT00990821** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 188 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting
- Postoperative Nausea and Vomiting

## Interventions

- **DRUG:** 90 mg MK-0517 (PS80)
- **DRUG:** 100 mg MK-0517 (PS80)
- **DRUG:** 100 MK-0517 (PS80) + 2 mg midazolam
- **DRUG:** 115 mg MK-0517 (PS80)
- **DRUG:** 150 mg MK-0517 (PS80)
- **DRUG:** 40 mg MK-0517 (non-PS80)
- **DRUG:** 100 mg MK-0517 (non-PS80)
- **DRUG:** 150 mg MK-0517 (Non-PS80)
- **DRUG:** Placebo
- **DRUG:** 40 mg Aprepitant
- **DRUG:** 125 mg Aprepitant
- **DRUG:** 2 mg Midazolam

## Key facts

- **NCT ID:** NCT00990821
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2005-12
- **Final completion:** 2006-01
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2015-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00990821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00990821, "A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00990821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*